Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.25
Bid: 1.20
Ask: 1.30
Change: 0.00 (0.00%)
Spread: 0.10 (8.333%)
Open: 1.25
High: 1.25
Low: 1.25
Prev. Close: 1.25
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Physiomics receives Innovate UK grant for cancer treatment project

Fri, 06th Jan 2017 12:28

(ShareCast News) - Systems biology company Physiomics confirmed on Friday that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Study Competition that was the subject of a provisional announcement on 22 November.The AIM-traded firm said the proposed project is titled 'Decision Support Systems For Stratified Cancer Treatment'.In line with its strategic objective to explore the personalised medicine market set out in its full year results, the objective of the project is to create a prototype decision support system to improve cancer care by helping medical professionals make treatment decisions based on patient specific data."The ultimate objective would be to create a practical tool that could be licensed initially to NHS providers in the UK to support clinical decision making and improve outcomes for individual patients suffering with certain types of cancer," Physiomics' board explained in a statement.In the first part of the project academic collaborator Professor Mark Middleton will provide anonymised data from individual patients with certain cancer types.Physiomics will then use its 'Virtual Tumour' technology to create a decision support tool that will prospectively suggest an optimal treatment regime for new patients presenting with these cancers.In the third part of the project, the Oxford Academic Health Science Network will develop an economic case and support the creation of a commercialisation plan for the tool."Once a prototype has been successfully developed, further funding is likely to be required to create a fully distributable commercial tool," the board said.The grant revenue is expected to be £132k over a twelve month period commencing February 2017, hence just under half of it is likely to be recognised in the company's current financial year."Some of this revenue will be used for disbursements to project collaborators and the balance will make a significant contribution towards the time spend by Physiomics personnel on the project."
More News
12 Mar 2015 11:53

UK WINNERS & LOSERS: SOCO Shares Plunge As Weak Oil Prices Take Toll

Read more
12 Mar 2015 08:26

Physiomics Raises GBP270,000 In Discounted Share Placing (ALLISS)

Read more
3 Mar 2015 13:06

Physiomics Shares Surge As It Gets Contract With Merck

Read more
2 Feb 2015 08:40

Physiomics Shares Up As It Terminates Equity Swap Deal Early

Read more
12 Nov 2014 13:06

UK MIDDAY BRIEFING: RBS, HSBC Hit With Fines, Barclays Still In Talks

Read more
12 Nov 2014 12:02

UK WINNERS & LOSERS: G4S And Tullow Oil Lead FTSE 100 Gainers

Read more
12 Nov 2014 10:47

Physiomics Optimistic On Virtual Tumour Platform Interest

Read more
4 Nov 2014 12:10

UK MIDDAY BRIEFING: Oil Stocks Down As Oil Price Hits 4-Year Low

Read more
4 Nov 2014 11:32

UK WINNERS & LOSERS: Imperial Tobacco Gains As Oil Stocks Slide

Read more
4 Nov 2014 08:27

Physiomics Shares Jump On Disclosure Of Merck As Partner

Read more
4 Nov 2014 08:21

UK MORNING BRIEFING: Legal & General, Imperial Tobacco Start Strongly

Read more
27 Oct 2014 11:11

UK WINNERS & LOSERS: Banks Under Stress After EU Test Results

Read more
27 Oct 2014 10:16

Physiomics Extends Collaboration With "Major" Pharmaceutical Company

Read more
7 Oct 2014 08:51

Physiomics Launches Web-Based Cardiac Toxicity Prediction Service

Read more
14 Aug 2014 15:41

Physiomics wins cancer therapy deal

Biology company Physiomics won a contract with an unidentified drug company on Thursday, boosting its shares by 18.75%. Under the deal, Physiomics will model immune therapy agents for cancer research by the end of the year on a fee-for-service basis. Physiomics' chief executive Mark Shadwick said:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.